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Abstract
Background: Improvement in treatment for patients with recurrent ovarian cancer is needed. Standard therapy in
patients with platinum-sensitive recurrent ovarian cancer consists of platinum-based chemotherapy. Median overall
survival is reported between 18 and 35 months. Currently, the role of surgery in recurrent ovarian cancer is not
clear. In selective patients a survival benefit up to 62 months is reported for patients undergoing complete
secondary cytoreductive surgery. Whether cytoreductive surgery in recurrent platinum-sensitive ovarian cancer is
beneficial remains questionable due to the lack of level I-II evidence.
Methods/Design: Multicentre randomized controlled trial, including all nine gynecologic oncologic centres in the
Netherlands and their affiliated hospitals. Eligible patients are women, with first recurrence of FIGO stage Ic-IV platinum-
sensitive epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer, who meet the inclusion criteria.
Participants are randomized between the standard treatment consisting of at least six cycles of intravenous platinum
based chemotherapy and the experimental treatment which consists of secondary cytoreductive surgery followed by
at least six cycles of intravenous platinum based chemotherapy. Primary outcome measure is progression free survival.
In total 230 patients will be randomized. Data will be analysed according to intention to treat.
Discussion: Where the role of cytoreductive surgery is widely accepted in the initial treatment of ovarian cancer, its
value in recurrent platinum-sensitive epithelial ovarian cancer has not been established so far. A better understanding
of the benefits and patients selection criteria for secondary cytoreductive surgery has to be obtained. Therefore the 4th
ovarian cancer consensus conference in 2010 stated that randomized controlled phase 3 trials evaluating the role of
surgery in platinum-sensitive recurrent epithelial ovarian cancer are urgently needed. We present a recently started
multicentre randomized controlled trial that will investigate the role of secondary cytoreductive surgery followed by
chemotherapy will improve progression free survival in selected patients with first recurrence of platinum-sensitive
epithelial ovarian cancer.
Trial registration: Netherlands Trial Register number: NTR3337.
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Background
Since overall survival is poor for patients with recurrent
platinum-sensitive ovarian cancer, improvement of treat-
ment is needed for these patients. Standard therapy in pa-
tients with platinum-sensitive recurrent ovarian cancer is
platinum-based chemotherapy [1]. In two large prospective
trials this resulted in a median overall survival of 18 and 29
months [2,3]. The recently published OCEANS trial, com-
pared carboplatin in combination with gemcitabine+/-
bevacizumab, and reported a median overall survival of
33-35 months [4]. The role of secondary debulking surgery
in recurrent ovarian cancer is not clear, and current prac-
tice differs widely between institutions. Several studies,
nearly all retrospective, with highly selected patients, have
demonstrated a survival benefit with survival rates up to
62 months for patients undergoing complete secondary
cytoreductive surgery [5]. Three studies evaluated the
predictive factors to accomplish complete secondary
cytoreductive surgery. The first, the Arbeitsgemeinschaft
Gynäkologische Onkologie (AGO) DESKTOP I study,
found three predictive factors for complete resection: good
performance status, no or small volume of ascites
(<500 ml), and complete primary surgery or FIGO I/II. In
these selected patients (AGO-score positive), complete
resection was achieved in 79% [6]. The second, the
DESKTOP II trial, prospectively validated the AGO score
and confirmed a complete resection rate of 76% [7]. How-
ever in this validation study only 57% of the score-positive
patients underwent a secondary debulking which may have
resulted in selection-bias and subsequently reduced valid-
ation. The third study of Tian et al. developed a risk model
with six predictive factors (FIGO stage, residual tumor
after primary surgery, PFI (months), ECOG performance
status, CA125 at recurrence (U/ml) and ascites at recur-
rence) [8]. This model categorizes patients as low or high
risk. In the low-risk group the proportion of complete
cytoreduction was 53.4% compared with 20.1% in the
high-risk group. Inclusion criteria of the current study are
based on predictive factors as observed in the mentioned
studies. Due to the retrospective nature of most studies
reporting on secondary cytoreductive surgery, information
on surgery related morbidity and second line chemo-
therapy is scarce. If secondary cytoreductive surgery causes
chemotherapy delays and/or dose reductions, is therefore
unknown Bristow et al. reported peri-operative morbidity
with a weighted mean of 19.2% [5] which seems compar-
able to morbidity in primary cytoreductive surgery [9].
Whether cytoreductive surgery in recurrent platinum-
sensitive ovarian cancer is really beneficial remains
questionable due to the lack of level I-II evidence [10].
Therefore, the 4th ovarian cancer consensus conference in
2010 stated that randomized controlled phase 3 trials that
evaluate the role of surgery in platinum-sensitive recurrent
ovarian cancer should be considered as a priority [11].
Objective
The aim of this study is to determine whether secondary
cytoreductive surgery followed by platinum-based chemo-
therapy increases progression-free survival in patients with
recurrent platinum sensitive epithelial ovarian cancer, pri-
mary peritoneal cancer or fallopian tube cancer.
Primary outcome measure
Primary outcome measure is progression free survival, de-
fined as the interval between the date of randomisation
and the date of progressive disease or death of any cause,
whatever occurs first. Progressive disease defined as clinical
and radiological signs of recurrence (RECIST 1.1 criteria)
[12] or elevated CA 125 (GCIG criteria) and radiological
signs of recurrence (RECIST 1.1 criteria) [13].
Secondary outcome measures
Secondary outcome measures are overall survival, progres-
sion free survival since start therapy and after the sixth
chemotherapy cycle, quality of life during two years after
treatment (EORTC QLQ-C30 version 3.0 and QLQ-OV28,
EQ-5D), surgery related morbidity and mortality, toxicity
(NCI-CTC Toxicity Scale Version 4.0), tumor response fol-
lowing treatment (RECIST and GCIG criteria).
Methods/Design
Study design
This study is a multicenter prospective randomised con-
trolled phase III trial in which all nine Dutch gynaecological
oncology centres and affiliated hospitals are participating.
Patients with first recurrence of platinum-sensitive epithe-
lial ovarian cancer, primary peritoneal cancer or fallopian
tube cancer will be randomly assigned to the control arm
and experimental arm in a 1:1 ratio. In the control arm pa-
tients receive the standard treatment for platinum-sensitive
recurrent ovarian cancer of at least six cycles of intravenous
platinum containing chemotherapy. In the experimental
arm treatment consists of secondary cytoreductive surgery
followed by at least six cycles of intravenous platinum con-
taining chemotherapy (Figure 1).
Eligibility criteria
Inclusion criteria patients
Patients, ≥ 18 years, with first recurrence of platinum-
sensitive (≥ 6 months after completion of front-line
platinum-taxol chemotherapy) epithelial ovarian cancer,
primary peritoneal cancer or fallopian tube cancer, are
eligible for this study and can be randomised after given
informed consent. First recurrence defined as clinical
and radiological signs of recurrence (RECIST 1.1 cri-
teria) or elevated CA 125 (GCIG criteria) and radio-
logical signs of recurrence (RECIST 1.1 criteria).
Inclusion criteria are FIGO stage Ic-IV (FIGO system
1988), first-line treatment consisted of complete or
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optimal (≤ 1 cm) cytoreductive surgery and (neo-adjuvant)
platinum-taxol based chemotherapy, ascites < 500 ml
(pocket < 8 cm on ultrasound examination), complete
resection seems possible (estimated by a gynaecologic
oncologist), good performance status (ECOG 0-1) and
administration of platinum based chemotherapy is
possible (appropriate laboratory values).
Exclusion criteria patients
Exclusion criteria are non-epithelial or borderline ovar-
ian tumours, platinum-refractory or resistant tumour,
secondary or later recurrence, prior or already planned
therapy with respect to recurrence, any disease, medical
history or medication not allowing surgery and/or plat-
inum based chemotherapy, concurrent treatment for
other primary malignancy except for carcinoma in situ
and basal or squamous cell carcinoma of the skin or
participation in interfering trial.
Requirement for participating hospitals
All hospitals can participate in this trial on the condi-
tion that chemotherapy in both arms is given by a regis-
tered medical oncologist and secondary cytoreductive
surgery is performed by a gynaecological oncologist in
one of the nine gynaecological oncology centres or one
of their affiliated hospitals certified as an ovarian cancer
treatment center. In addition, approval by the local
Institutional Medical Ethics Committee (MEC) must be
settled.
Patient recruitment
All eligible patients will be evaluated by a multidisciplinary
team consisting of at least a gynaecological oncologist, a
medical oncologist and an experienced radiologist. Con-
firmation of recurrent ovarian cancer by cytological or
histological investigation is warranted if there is any doubt
regarding an abnormal finding on CT-scan. Diagnostic
laparoscopy is allowed to estimate whether complete re-
section is possible and has to be performed by a gynaeco-
logical oncologist. All patients who meet the inclusion
criteria, will be asked to participate in this study. After
obtaining written informed consent, randomisation can
take place.
Randomisation
Randomisation is performed by accessing a central
internet-based randomisation programme. Stratification
will be done for gynaecologic-oncologic center hospital
and completeness of primary cytoreductive surgery
(complete vs optimal). Patients will be randomly allo-
cated to both arms in a 1:1 ratio. To ensure patients
privacy, patients will be registered by study trial number
after randomisation.
Pre-treatment evaluation
Patients in both treatment arms should be asked to fill out
a baseline quality of life questionnaire (EORTC QLQ-C30
version 3.0 and QLQ-OV28, EQ-5D). Furthermore, CA
125 must be determined and a Case Report Form (CRF)
with respect to baseline characteristics must be completed.
In-and exclusion criteria
Platinum-based
chemotherapy
At least six cycles
Secondary 
cytoreductive surgery
First recurrence of platinum-
sensitive epithelial ovarian 
cancer, primary peritoneal 
cancer or fallopian tube cancer
Informed consent
Randomisation (1:1)
Platinum-based
chemotherapy
At least six cycles
Figure 1 SOCceR trial study design.
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Interventions
Control arm
Patients in the control arm will receive at least six courses
of platinum-containing chemotherapy. The first course
should be given as soon as possible but within 4 weeks
after randomisation. Chemotherapy dose and schedule,
combination with other chemotherapeutic agents and pre-
and post-chemotherapy medication and hydration is left
to the discretion of the participating center. Before every
chemotherapy cycle, hematological, renal, and hepatic
function will be determined and toxicity is scored using
the common toxicity criteria for adverse effects (CTCAE)
version 4.0.
Experimental arm
Secondary cytoreductive surgery must be performed within
4 weeks after randomisation. All patients will be prepared
for the possibility of a bowel stoma. Surgery is carried out
under antibiotic prophylaxis. The combination of antibi-
otics will be according local standards. The objective of the
surgical intervention is complete resection of all visible dis-
ease. The extensiveness of surgery is left to the discretion
of the gynaecological oncologist. The surgical procedure
should start with obtaining a peritoneal fluid sample for
cytology. Patients who have at least 500 ml of peritoneal
fluid at the time of laparotomy are considered positive for
ascites. To gain proper insight in the tumor spread, all ad-
hesions from any previous surgery have to be excised. This
is followed by a thorough inspection and palpation of the
intra-abdominal and retroperitoneal contents. The extend
of tumor growth is carefully recorded in eight abdominal
regions. In case of peritonitis the number of tumor de-
posits will be recorded. Based on this information, a plan
for dissection is made. At the end of the cytoreductive pro-
cedure, the extensiveness of surgery, duration of the oper-
ation, the amount of blood loss and the amount of residual
tumor is recorded. Secondary cytoreductive surgery is con-
sidered complete if there is no tumor left, optimal if the
largest residual tumor is ≤ 1 cm and suboptimal if more
than 1 cm residual tumor (diameter (length, width or
depth) of the separate tumor depositions) is left. The first
chemotherapy course should be given as soon as possible
but within 6 weeks after surgery.
Post-treatment evaluation
In both treatment arms, evaluation of response will take
place before the fourth chemotherapy course and within
six weeks after the sixth chemotherapy course. This
evaluation consists of determining CA 125 (GCIG cri-
teria) and performing a CT-scan (RECIST 1.1). Toxicity
is scored using the common toxicity criteria for adverse
effects (CTCAE) version 4.0. Patients will be asked to fill
out a quality of life questionnaire (EORTC QLQ-C30
version 3.0 and QLQ-OV28, EQ-5D). After cytoreductive
surgery in the experimental arm, haemoglobin must be
determined. A Case Report Form (CRF) with respect to
the chemotherapeutic treatment and operation must be
completed.
Follow-up
As the primary outcome measure of this study is pro-
gression free survival, strict follow-up is warranted. After
completion of therapy, the patients will be evaluated by
their gynaecological oncologist/gynaecologist and med-
ical oncologist every three months for the first two years
and twice annually during the third, fourth and fifth
year. At each outpatient control, patient’s history need
to be obtained and CA 125 will be determined. A CT-
scan has to be performed if there are clinical symptoms
and CA 125 is in the normal range (0-35 U/ml) or if CA
125 is increased according to the GCIG criteria and
there are no clinical symptoms. As overall survival is
one of the secondary endpoints, follow-up of each pa-
tient in the study will be at least three years with a max-
imum of five years. Any treatment for second, third or
later recurrence has to be documented. All data will be
registered on a follow-up Case Record Form (CRF).
Quality of life
Health-related quality of life (HRQL) is one of the second-
ary endpoints in this study. It will be assessed with self-
reported questionnaires (EORTC QLQ-C30 version 3.0
and QLQ-OV28, EQ-5D) to evaluate the impact of sec-
ondary cytoreductive surgery added to platinum based
chemotherapy. The questionnaires have to be filled out
after the sixth chemotherapy cycle and at 3, 6, 9, 12, 18
and 24 months following treatment.
Assessment of serious adverse events
A serious adverse event (SAE) related to surgery and/or
chemotherapy will be collected and recorded on the Ser-
ious Adverse Event Report Form during every trial
phase. They all must be reported to the principal investi-
gator within 24 hours and will be followed until they
have abated or until a stable situation has been reached.
Statistical analysis
Sample size
Progression free survival of patients in the control arm
is estimated at ten months. An increase in progression
free survival of at least five months in favor of the ex-
perimental treatment is considered acceptable given the
expected surgery related morbidity. To detect a constant
hazard ratio of 1.5 with a 0.05 two-sided significance
level and a power of 80%, 104 patients should be en-
rolled in each arm. Assuming an accrual period of five
years, three years of follow-up and 10% loss to follow
up, 230 patients need to be included.
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Interim analysis
An interim analysis for efficacy is planned at two months
after randomisation of the last patient. Whatever the out-
come of the interim analysis, all randomised patients will
be followed until 36 months after randomisation of the
last patient. This means that even in case of a statistically
significant treatment effect, the trial will not be stopped.
The objective of this interim analysis is that patients who
are not participating in this study might profit in case of
early positive results. The Peto-Haybittle rule, that re-
quires P <0.001 as evidence, will be applied. This leaves
the significance level of the final primary efficacy analysis
at 0.0498.
Data analysis
The results of the study will be analyzed according to
the intention to treat principle. All patients will be in-
cluded in the analysis and patients lost to follow-up will
be regarded as censored observations. Progression free
and overall survival in both treatment arms will be cal-
culated by the Kaplan-Meier method and compared by
using the log-rank test, assuming that the hazard rates
in the two treatment arms are roughly proportional over
time. If mortality due to surgery is unexpectedly high,
resulting in proportional hazard (PH) assumptions that
are not valid, the primary comparison of the treatment
groups will be based on the one-year progression-free
disease rates. In addition, progression free and overall
survival since start therapy and after the sixth chemo-
therapy cycle will be compared.
To adjust for baseline covariates, we will also estimate
the treatment effect by Cox’s proportional hazard (PH)
regression model, given that the PH assumptions are
valid. If the mortality due to surgery is unexpectedly
high, resulting in PH assumptions that are not valid,
progression free survival since start chemotherapy will
be analyzed. At least the following baseline covariates
will be considered: completeness of primary surgery,
FIGO stage, ECOG performance status, age, disease free
interval and CA-125 at recurrence. The significance level
of the final primary analysis will be set at 0.0498, and for
the interim analysis at 0.001. For all other analyses, 0.05
will be used in the report of study results.
Treatment related morbidity at 30 days after surgery will
be analysed with descriptive statistics. Logistic regression
will be used to study relations between clinical variables
and morbidity. Toxicity after the third and sixth chemo-
therapy course will be evaluated by means of descriptive
statistics and by using an unpaired Student’s t-test or the
two-sided Mann-Whitney test for the continuous vari-
ables. Comparisons of the proportions of toxicity between
the 2 arms will be done by use of a two-sided chi-square
test or a two-sided Fisher’s exact test if the number of ex-
pected patients in a given category is less than five.
Quality of life scores will be summarized per time-
point, for those subjects, who are alive, once for the ori-
ginal values and once for the changes from baseline.
Only subjects who have filled in a baseline questionnaire
will be included in the analysis. In addition to descriptive
statistics, the Quality Adjusted Life Years (QALY) will be
analysed. QALYs will be based on the EQ-5D-3 L ques-
tionnaire. The repeated measures indexes will be com-
bined over time using the trapezium rule (area under
the Quality Adjusted Life Year curve).
Safety reviews and monitoring
The SOCceR study has established an Independent Data
Safety Monitoring Board (DSMB) comprising of inde-
pendent experts who have no conflict of interest and agree
with the outline of the protocol. The committee will meet
once a year. Following this meeting, the DSMB will report
to the Study Coordinators about (serious) adverse events,
whether or not recruitment is on target and the compli-
ance with the QoL assessments is adequate. The commit-
tee may recommend changes in the conduct of the trial
and exclusion of a single center if excessive rates of mor-
bidity are present. All data presented at this meeting will
be considered confidential. During the study, the commit-
tee may decide to change the frequency of discussion.
Safety reviews are planned primarily to guard against
unfavorable results in the experimental arm. Death and
failure rates and SAE reports for both treatment arms will
be closely monitored in order to pick up any (unexpected)
trends. Safety reviews will be presented confidentially to
the DSMB every six months, and/or at request of the
DSMB. These biannual reviews will include data on num-
ber and causality of deaths, number of treatment failures
and serious adverse events. The DSMB can recommend to
modify or stop the study prematurely, if number and caus-
ality of deaths, number of treatment failures and serious
adverse events are significantly greater than was foreseen
in the literature. The assessment of the DSMB, will be pre-
sented to the principal investigators and will be reported
in the annual progress report to the accredited Medical
Ethics Committee.
Ethics
The study will be conducted in full conformance with the
ethical principles of the Declaration of Helsinki and in ac-
cordance with the Medical Research Involving Human
Subjects Act (WMO). It has been approved by the
Radboud Medical-Ethical Committee (ref. no MEC 2011/
426). The protocol is registered in the Dutch Trial Register
number NTR333. Before the start in other centres, the
protocol will be approved by local medical ethical commit-
tees. Ethical approval has already been obtained by the fol-
lowing local Ethics committees: Clinical Trial Center of
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the Maastricht University Medical Center, Ethics commit-
tee of the Academic.
Medical Centre Amsterdam, Ethics committee of the
Netherlands Cancer Institute/Antoni van Leeuwenhoek
Hospital, Committee of medical Ethics of the Leiden
University Medical Center, Ethics committee of the
University Medical Center Groningen, Landsteiner Institute
of the Groene Hart Hospital, Ethics committee of the
Catharina Hospital, Science agency of the TweeSteden
Hospital, Ethics committee of the Medical Spectrum
Twente, Ethics committee of the Bronovo Hospital, Ethics
committee of the Bernhoven Hospital and Ethics commit-
tee of the Atrium Medical Center.
The rationale, design and aims of the study will be ex-
plained to each patient along with the specific information
on the respective treatment arms. The principles of ran-
domisation and registration and the follow-up procedure
will be clarified. The patient will receive written patient in-
formation and will have ample opportunity to ask ques-
tions. The patient will have sufficient time to consider the
study before deciding to participate. Written informed
consent of the patient is required before randomisation.
Patients will also receive written information on the trial
insurance that covers for damage through injury or death
caused by the study.
Quality assurance
To enable peer review and/or inspections from Health
Authorities, the principal investigator will keep records,
including the identity of all participating subjects (suffi-
cient information to link records, e.g. CRFs and hospital
records), all original signed Informed Consent Forms
and copies of all CRFs, for 15 years.
Discussion
Other clinical trials
Currently, there are two other ongoing randomized con-
trolled trials: the DESKTOP III trial (NCT01166737) and
the GOG 213 trial (NCT00565851). The DESKTOP III trial
will compare overall survival in patients with platinum-
sensitive recurrent ovarian cancer with a positive AGO-
score randomized to cytoreductive surgery followed by
chemotherapy of physician’s choice versus chemotherapy of
physician’s choice alone whereas the GOG 213 trial will de-
termine if surgical secondary cytoreduction in addition to
adjuvant chemotherapy comprising carboplatin and pacli-
taxel with or without bevacizumab increases the duration
of overall survival of patients with recurrent platinum-
sensitive ovarian epithelial cancer, primary peritoneal cavity
cancer, or fallopian tube cancer. A better understanding of
the real advantages and disadvantages and patient’s selec-
tion criteria for secondary cytoreductive surgery will be
achieved after the completion of these three ongoing trials.
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